糖尿病对钠-葡萄糖协同转运蛋白-2抑制剂肾脏结局效应的影响:大型安慰剂对照试验协作荟萃分析
这项系统综述与荟萃分析纳入13项双盲、安慰剂对照、每组≥500例、≥6个月的大型SGLT2抑制剂试验,共90 409例参与者(82.7%有糖尿病,17.3%无糖尿病)。与安慰剂相比,SGLT2抑制剂使肾脏病进展风险降低37%(RR 0.63,95%CI 0.58-0.69),急性肾损伤风险降低23%(RR 0.77,95%CI 0.70-0.84),心血管死亡或心衰住院风险降低23%(RR 0.77,95%CI 0.74-0.81),有无糖尿病者效应相似。心血管死亡风险降低(RR 0.86,95%CI 0.81-0.92),非心血管死亡无显著降低(RR 0.94,95%CI 0.88-1.02)。作者认为,随机数据支持SGLT2抑制剂用于改变肾脏病进展和急性肾损伤风险,不仅适用于高心血管风险的2型糖尿病患者,也适用于慢性肾脏病或心衰患者,而不论糖尿病状态、原发性肾脏病或肾功能。
要点
- SGLT2抑制剂使肾脏病进展风险降低37%(RR 0.63,95%CI 0.58-0.69),有无糖尿病者RR相似。
- SGLT2抑制剂使急性肾损伤风险降低23%(RR 0.77,95%CI 0.70-0.84),有无糖尿病者效应相似。
- SGLT2抑制剂使心血管死亡或心衰住院风险降低23%(RR 0.77,95%CI 0.74-0.81),有无糖尿病者效应相似。
- 心血管死亡风险降低(RR 0.86,95%CI 0.81-0.92),非心血管死亡无显著降低(RR 0.94,95%CI 0.88-1.02)。
- 基于绝对效应估计,SGLT2抑制的绝对获益超过酮症酸中毒或截肢的任何严重危害。
适用人群与场景
- 纳入标准:双盲、安慰剂对照、成人(年龄≥18岁)、大型(每组≥500例参与者)、至少6个月疗程的SGLT2抑制剂试验。
- 共分析90 409例参与者:74 804例(82.7%)有糖尿病(>99%为2型糖尿病),15 605例(17.3%)无糖尿病;试验水平平均基线eGFR范围37-85 mL/min per 1.73 m2。
研究设计与关键结果
- 研究类型:系统综述与荟萃分析,纳入13项双盲、安慰剂对照、每组≥500例、至少6个月的大型SGLT2抑制剂试验,共90 413例参与者,排除4例糖尿病状态不确定者后分析90 409例。
- 主要疗效结局:肾脏病进展(标准化定义为随机化后eGFR持续下降≥50%、持续性低eGFR、终末期肾病或肾衰竭死亡)风险降低37%(RR 0.63,95%CI 0.58-0.69),有无糖尿病者RR相似;在4项慢性肾脏病试验中,不论原发性肾脏诊断如何RR相似。
- 急性肾损伤风险降低23%(RR 0.77,95%CI 0.70-0.84),心血管死亡或心衰住院复合风险降低23%(RR 0.77,95%CI 0.74-0.81),有无糖尿病者效应相似。
- 心血管死亡风险降低(RR 0.86,95%CI 0.81-0.92),非心血管死亡风险无显著降低(RR 0.94,95%CI 0.88-1.02);这些死亡结局的RR在有无糖尿病者中相似。
- 所有结局在不同试验平均基线eGFR水平下结果大体相似。
- 基于绝对效应估计,SGLT2抑制的绝对获益超过酮症酸中毒或截肢的任何严重危害。
- 主要安全结局为酮症酸中毒和下肢截肢。
证据类型、等级与局限
- 证据类型:对13项大型双盲、安慰剂对照随机试验的系统综述与荟萃分析(协作荟萃分析)。
- 研究注册:PROSPERO,CRD42022351618。
- 检索数据库:MEDLINE和Embase,检索时间从数据库建库至2022年9月5日。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,随机数据支持SGLT2抑制剂用于改变肾脏病进展和急性肾损伤风险,不仅适用于高心血管风险的2型糖尿病患者,也适用于慢性肾脏病或心衰患者,而不论糖尿病状态、原发性肾脏病或肾功能。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Large trials have shown that sodium glucose co-transporter-2 (SGLT2) inhibitors reduce the risk of adverse kidney and cardiovascular outcomes in patients with heart failure or chronic kidney disease, or with type 2 diabetes and high risk of atherosclerotic cardiovascular disease. None of the trials recruiting patients with and without diabetes were designed to assess outcomes separately in patients without diabetes.
METHODS: We did a systematic review and meta-analysis of SGLT2 inhibitor trials. We searched the MEDLINE and Embase databases for trials published from database inception to Sept 5, 2022. SGLT2 inhibitor trials that were double-blind, placebo-controlled, performed in adults (age ≥18 years), large (≥500 participants per group), and at least 6 months in duration were included. Summary-level data used for analysis were extracted from published reports or provided by trial investigators, and inverse-variance-weighted meta-analyses were conducted to estimate treatment effects. The main efficacy outcomes were kidney disease progression (standardised to a definition of a sustained ≥50% decrease in estimated glomerular filtration rate [eGFR] from randomisation, a sustained low eGFR, end-stage kidney disease, or death from kidney failure), acute kidney injury, and a composite of cardiovascular death or hospitalisation for heart failure. Other outcomes were death from cardiovascular and non-cardiovascular disease considered separately, and the main safety outcomes were ketoacidosis and lower limb amputation. This study is registered with PROSPERO, CRD42022351618.
FINDINGS: We identified 13 trials involving 90 413 participants. After exclusion of four participants with uncertain diabetes status, we analysed 90 409 participants (74 804 [82·7%] participants with diabetes [>99% with type 2 diabetes] and 15 605 [17·3%] without diabetes; trial-level mean baseline eGFR range 37-85 mL/min per 1·73 m2). Compared with placebo, allocation to an SGLT2 inhibitor reduced the risk of kidney disease progression by 37% (relative risk [RR] 0·63, 95% CI 0·58-0·69) with similar RRs in patients with and without diabetes. In the four chronic kidney disease trials, RRs were similar irrespective of primary kidney diagnosis. SGLT2 inhibitors reduced the risk of acute kidney injury by 23% (0·77, 0·70-0·84) and the risk of cardiovascular death or hospitalisation for heart failure by 23% (0·77, 0·74-0·81), again with similar effects in those with and without diabetes. SGLT2 inhibitors also reduced the risk of cardiovascular death (0·86, 0·81-0·92) but did not significantly reduce the risk of non-cardiovascular death (0·94, 0·88-1·02). For these mortality outcomes, RRs were similar in patients with and without diabetes. For all outcomes, results were broadly similar irrespective of trial mean baseline eGFR. Based on estimates of absolute effects, the absolute benefits of SGLT2 inhibition outweighed any serious hazards of ketoacidosis or amputation.
INTERPRETATION: In addition to the established cardiovascular benefits of SGLT2 inhibitors, the randomised data support their use for modifying risk of kidney disease progression and acute kidney injury, not only in patients with type 2 diabetes at high cardiovascular risk, but also in patients with chronic kidney disease or heart failure irrespective of diabetes status, primary kidney disease, or kidney function.
FUNDING: UK Medical Research Council and Kidney Research UK.
参考来源
- Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet. 2022. PMID: 36351458. doi:10.1016/S0140-6736(22)02074-8
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。